On July 4, InSmart announced that it delivered its second preclinical compound candidate (PCC) to its R&D partner, Fosun Pharma (600196.SH; 02196.HK), in June this year. This is a potential innovative therapy targeting synthetic lethal strategies for solid tumor treatment, and Insilicent looks forward to submitting a pre-IND communication and application for this candidate to the Drug Review Center of the State Drug Administration in the fourth quarter of 2024.

For more information, please download the attached file